1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |